Table 3 Representative clinical trials for the combination of ICIs and CAR-T therapy
From: Exploring treatment options in cancer: tumor treatment strategies
Clinical Trials No. | Phase | No. Infused Patients | Combination regimens | Cancer Type | Preliminary Results | Â |
|---|---|---|---|---|---|---|
| Â | Â | Â | ICI | CAR-T Target | Â | Â |
NCT01822652 | I | 11 | Pembrolizumab | GD2 | Neuroblastoma | 6 PD, 2 CR (after salvage), 5 SD |
NCT02414269 | I | 27 | Pembrolizumab | Mesothelin | Malignant pleural diseases, comprising metastatic lung and breast cancers and malignant pleural mesothelioma | 2 CR, 8 SD (>6mons) |
NCT03287817 | I | 19 | Pembrolizumab | CD19/22 dual target | r/r DLBCL | 64% ORR, 55% CRR |
NCT03630159 | Ib | 4 | Pembrolizumab | CD19 | r/r DLBCL | 1 PR, 2 PD |
NCT03726515 | I | 7 | Pembrolizumab | EGFRvIII | EGFRvIII + , MGMT-unmethylated glioblastoma | Low efficacy, 7 PD, median PFS: 5.2mons, median OS: 11.8months |
NCT04991948 | Ib | Estimated 34 | Pembrolizumab | NKG2D | Colorectal Cancer | 2 Deaths reported. Paused |
NCT04995003 | I | Estimated 25 | Pembrolizumab or nivolumab | HER-2 | Advanced Sarcoma | NA |
NCT04003649 | I | Estimated 60 | Nivolumab and Ipilimumab | IL13Ra2 | Glioblastoma | NA |
NCT04539444 | II | 16 | Tislelizumab | CD19/22 dual target | R/R B-NHL | CR 11, 1-year PFS: 68.8%, 1-year OS: 81.3% |
NCT04381741 | Ib | 8 | Tislelizumab | CD19 | R/R DLBCL | 4 CR, 1 PR, 2 PD |
NCT02926833 | I/II | 28 | Atezolizumab | CD19 | DLBCL | 75% ORR, 46% CR, 29% PR,7%SD, 14%PD |
NCT02706405 | I | 29 | Durvalumab | CD19 | R/R LBCL | 35% ORR, 27% CR |
NCT03310619 | I/II | Estimated 77 | Durvalumab, Nivolumab, Relatlimab | CD19 | R/R aggressive B-cell NHL | NA |
